Archives
-
Brinzolamide Nanoemulsions: Corneal Delivery and Safety
2026-09-24
Mahboobian and colleagues evaluated brinzolamide-loaded nanoemulsions using bovine-cornea permeation and complementary cell-based and tissue-based irritation tests. Seven of the twelve formulations showed greater ex vivo penetration than a marketed brinzolamide suspension, while two formulations showed no irritation in the reported HET-CAM and BCOP tests.
-
From MRSA Membrane Damage to Immune Context
2026-09-23
YZ462 highlights bacterial membranes as a promising target in MRSA research. The next translational step is to separate direct antibacterial activity from host immune effects—and to test each with appropriately designed experiments.
-
Liraglutide, AVP, and the Brain–Kidney Axis
2026-09-23
Greenwood and colleagues combine a clinical before-and-after study with pituitary proteomics, phosphoproteomics, a functional AVP luciferase assay, and kidney analysis to investigate how liraglutide affects fluid homeostasis. Their findings connect reduced circulating vasopressin with sex- and time-dependent synaptic signaling changes and downstream aquaporin 2 regulation, providing a mechanistic framework for interpreting GLP-1 receptor agonist effects on renal water handling.
-
Miltefosine: From PI3K/Akt to Neutrophil Recovery
2026-09-22
Miltefosine is more than a PI3K/Akt pathway inhibitor: emerging evidence links it to Ras/MEK/ERK-dependent neutrophil differentiation and hematopoietic recovery. This thought-leadership analysis translates those findings into a decision framework for oncology, hematology, and translational research teams.
-
From P2RX1 Signaling to Apoptosis Assay Strategy
2026-09-22
Mechanistic studies in Philadelphia chromosome-positive acute lymphoblastic leukemia show how P2RX1, calcium, CaMKII, PI3K/Akt signaling, and mitochondrial dysfunction can shape tyrosine kinase inhibitor responses. This article translates those findings into a practical framework for using the Annexin V-Cy5/DAPI Apoptosis Kit to distinguish viable, apoptotic, and membrane-compromised cells without overstating what a surface-death assay can prove.
-
0.4% Trypan Blue Solution: Practical Guide
2026-09-21
0.4% Trypan Blue Solution provides a rapid visual method for cell viability measurement, live/dead cell discrimination, and routine cell counting. It is intended for research workflows such as cell culture and cytotoxicity assays, but it is not a diagnostic, medical, or standalone method for identifying apoptosis or necrosis.
-
Mdivi-1 and ECM-Driven Mitochondrial Fission
2026-09-21
Explore how Mdivi-1, a selective DRP1 inhibitor, can test the causal link between extracellular-matrix remodeling, mitochondrial fission, stress responses, and apoptosis in advanced cell-based assays.
-
RRP Restores Lipid Metabolism in Hepatic I/R Injury
2026-09-20
This Journal of Ethnopharmacology study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol handling, not only by providing nonspecific antioxidant protection. Its mechanistic model connects AMPK–mTOR signaling with suppression of SCAP–SREBP2 cholesterol synthesis and activation of LXRα-dependent cholesterol efflux, offering a useful framework for lipid metabolism research and hepatocyte assay design.
-
H2S Deficiency and ER Stress in Diabetic Cardiomyopathy
2026-09-19
The reference study identifies reduced endogenous hydrogen sulfide production as a mechanistic component of lipotoxic myocardial injury in diabetic cardiomyopathy, linking H2S deficiency to endoplasmic reticulum stress, lipid accumulation, and apoptosis. Its patient, animal, and cardiomyocyte models also show that H2S donation and ER-stress inhibition can mitigate these abnormalities, providing a framework for studying H2S biology with complementary dynamic assays.
-
Coelenterazine B6010 for Reliable ROS Assays
2026-09-18
This scenario-driven guide explains how Coelenterazine, SKU B6010, can support reporter-gene studies, superoxide anion assays, BRET, oxidative stress measurement, and cancer-associated ROS imaging. It emphasizes solvent control, signal interpretation, protocol optimization, and practical vendor-selection criteria for more defensible cell-based data.
-
EDC.HCl Coupling Workflow Guide
2026-09-18
EDC.HCl provides a water-soluble way to activate carboxyl groups for amide bond formation with primary amines in controlled laboratory workflows. It is suitable for in vitro peptide, bioconjugation, and related synthetic work, but the dossier provides no in vivo or clinical data to support animal, therapeutic, or clinical use.
-
Electrical Stimulation Enhances Nanoparticle Uptake
2026-09-17
The reference study shows that alternating-current electrical stimulation increases magnetic nanoparticle endocytosis in several cancer cell models, primarily through macropinocytosis associated with altered F-actin and intracellular Ca2+. The resulting increase in intracellular nanoparticles improves both magnetic hyperthermia performance and MRI signal intensity, offering a potentially generalizable physical strategy that avoids nanoparticle surface functionalization.
-
Acetylspiramycin: A Smarter Resistance Workflow
2026-09-17
A translational framework for using Acetylspiramycin (Spiramycin B) to connect ribosomal mechanism, resistant Mycoplasma pneumoniae phenotypes, assay design, and emerging host-response questions.
-
Oligomycin A for Immunometabolic Assay Design
2026-09-16
Oligomycin A provides a direct way to separate ATP synthase-dependent respiration from glycolytic compensation in cancer and macrophage models. This practical guide connects mitochondrial flux measurements with the 25-hydroxycholesterol–AMPK–STAT6 axis described in the reference study, while emphasizing controls, dose optimization, and interpretation limits.
-
CXCL1–CXCR2 Signaling in Pancreatic Cancer Pain
2026-09-16
A study in Brain, Behavior, and Immunity identifies the nucleus tractus solitarii as a central site where CXCL1–CXCR2 signaling activates microglia and promotes pancreatic cancer-induced pain. Its combination of transcriptomics, neural measurements, local pharmacology, and behavioral analysis provides evidence for a neuroimmune pain circuit that may complement peripheral cancer-pain research.